Roche said the test strips are expired or nearly expired products that are repackaged with counterfeit labels bearing Roche's ...

Roche was quick to note that the test’s performance was “only minimally impacted” by the patients’ age, sex, body mass index ...

Roche, the parent company of Indianapolis-based Roche Diagnostics, said it received FDA clearance to sell a new test to help determine a patient’s risk of an often untested but common ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion ... With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics ...

Roche and Eli Lilly have started testing a blood test that could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain scans and speeding up the ...

Roche Tissue Diagnostics also collaborates with dozens of pharmaceutical companies to test and develop better tools for evaluating cancer treatments. It doesn't engage in animal testing or conduct ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with so-called “HER2-ultralow” status. The company’s PATHWAY HER2 ...

Roche has obtained U.S. government green lights ... influenza B and strep throat, as well as an in-lab test for Clostridium difficile, or C. diff.

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

1 The Roche Diagnostics Tina-quant® Lipoprotein (a) Gen.2 Molarity assay is an in-vitro test measuring lipoprotein (a) in a person's bloodstream (serum and plasma), and will be broadly available ...

Roche Diagnostics is cutting an unspecified number of jobs at two locations in Central Indiana as it struggles to cope with changing conditions in the diabetes care market. Company spokesman Todd ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. | After Novartis and Roche grew their sales last year, the ...